Evidence map›Paper›PMID 21463128›Full record

ArticleLeukemia & lymphoma2011

Response of hairy cell leukemia to bendamustine.

Robert J Kreitman, Evgeny Arons, Maryalice Stetler-Stevenson, Kenneth B Miller

Abstract readCase ReportsLetter
In one paragraph

Article in Leukemia & lymphoma, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Review
  3. Review
  4. Article
  5. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013
    Article
  6. My treatment approach to hairy cell leukemia.Mayo Clinic proceedings · 2012
    Article
  7. Immunoconjugates and new molecular targets in hairy cell leukemia.Hematology. American Society of Hematology. Education Program · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Robert J Kreitman
Evgeny Arons
Maryalice Stetler-Stevenson
Kenneth B Miller

Funding

Flow Cytometric Analysis of Benign and Malignant TumorsZICSC009372 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI WANG, HAO-WEI · 2009 to 2025
$29.6M
Development of Recombinant Toxins to Treat Hematologic MalignanciesZIABC010301 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KREITMAN, ROBERT · 2009 to 2025
$21.7M
Flow Cytometric Evaluation of BiomarkersZICBC011104 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, HAO-WEI · 2009 to 2025
$8.6M
RECOMBINANT TOXINS FOR TREATMENT OF PATIENTS WITH HEMATOLOGIC MALIGNANCIESZ01BC010301 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KREITMAN, ROBERT · 1998 to 2008
$1.5M
Intramural NIH HHS Z01 BC010301Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Agents, AlkylatingBendamustine HydrochlorideHumansInterleukin-2 Receptor alpha SubunitLeukemia, Hairy CellMaleMiddle AgedNitrogen Mustard CompoundsSialic Acid Binding Ig-like Lectin 2Treatment OutcomeTumor BurdenAntineoplastic Agents, AlkylatingBendamustine HydrochlorideInterleukin-2 Receptor alpha SubunitNitrogen Mustard CompoundsSialic Acid Binding Ig-like Lectin 2

Identifiers

PMID21463128
PMCPMC7437359

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.